Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports First Quarter 2017 Financial Results
May 09, 2017 16:02 ET | FibroGen, Inc.
SAN FRANCISCO, May 09, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the first quarter of 2017 and provided...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Fiscal 2016 Financial Results
March 01, 2017 16:02 ET | FibroGen, Inc.
SAN FRANCISCO, March 01, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Financial Results for the First Quarter of 2016
May 09, 2016 16:02 ET | FibroGen, Inc.
Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data –Webcast Conference Call Scheduled for 4:30pm EST Today– SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE)...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report First Quarter 2016 Financial Results on May 9, 2016
May 02, 2016 16:05 ET | FibroGen, Inc.
SAN FRANCISCO, May 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis
March 11, 2016 08:00 ET | FibroGen, Inc.
SAN FRANCISCO, March 11, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (FibroGen) announced today that the European Respiratory Journal (“ERJ”) published on-line a manuscript...